Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 249-655-6 | CAS number: 29463-06-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1990-11-19 to 1991-02-19
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP and similar to guideline study.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 991
- Report date:
- 1991
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- GLP compliance:
- yes
- Remarks:
- This study was conducted in compliance with Part 792 of 40 CFR (EPA/TSCA Good Laboratory Practice Regulations)
- Limit test:
- no
Test material
- Reference substance name:
- Tris(2-hydroxyethyl)methylammonium methyl sulphate
- EC Number:
- 249-655-6
- EC Name:
- Tris(2-hydroxyethyl)methylammonium methyl sulphate
- Cas Number:
- 29463-06-7
- Molecular formula:
- C7H18NO3.CH3O4S
- IUPAC Name:
- 1,5-dihydroxy-3-(2-hydroxyethyl)pentan-3-aminium methyl sulfate
- Details on test material:
- - Sample No of test material: 38218-A- Substance type: organic- Physical state: cloudy liquid- Purity: 90 % Triethanol Methyl Ammonium Methyl Sulfate; 10 % Isopropyl alcohol- Expiration date of the lot/batch: August 1992- Storage condition of test material: in a temperature monitored room- Lot/batch: 2005211- Density: 1. 229 g/mL
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS- Source: Charles River Breeding Laboratories Inc., Kingston, New York 12484, USA- Age at study initiation: approx. 39 weeks old- Weight at study initiation: male: 176.4 g (163.5-188.3); female: 166.5 g (152.6-183.5)- Fasting period before study: no- Housing: individually- Diet: ad libitum, standard laboratory diet (Purina Mills Certified Rodent Mash-type Diet #5002)- Water: ad libitum, tap water (Elizabethtown Water Company, Westfield, N.J., USA)- Acclimation period: 11 daysENVIRONMENTAL CONDITIONS- Temperature (°C): 20.6 - 25.6- Humidity (%): 28 - 70- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: drinking water
- Vehicle:
- water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:Appropriate amounts of the test material were mixed with tap water to achieve the desired concentrations. Test solution with 1.6 % was prepared by measuring 231.1 mL of the stock solution in an appropriately sized beaker and fill up with 13 liters of tap water. 0.32 % solutions were prepared by diluting 2200 mL of the 1.6 % solution with 11 liters of tap water. 0.096 % solutions were prepared by diluting 660 mL of the 1.6 % solution with 11 liters of tap water.All preparations were mixed thoroughly.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- No details on analytical measurements were included in the study report. But homogeneity, stability and confirmation of concentrations during study were analysed. Homogeneity was proven prior to initiation by analysis of mock batches of the low and high concentration solution. Samples of each test solution (dose level) for weeks 1 through 4, 7, 8, and 12 were sent to the sponsor for concentration verification. Stability analysis was performed in the low and high concentration solutions 4, 7 and 14 days after preparation of the testing solutions.
- Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:0.096 % v/v (eq. 115.3 (m) and 139.6 (f) mg/kg bw/d)Basis:nominal in water
- Remarks:
- Doses / Concentrations:0.32 % v/v (eq. 406.4 (m) and 495.5 (f) mg/kg bw/d)Basis:nominal in water
- Remarks:
- Doses / Concentrations:1.6 % v/v (eq. 2389.1 (m) and 2703.3 (f) mg/kg bw/d)Basis:nominal in water
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes- Time schedule: daily- Parameters examined: normality, emesis, abnormal stools, other discharges and gross signs of poor health or toxic or pharmacologic effects, e.g. gross abnormalities in general condition, appearance, activity, behaviour, etc.DETAILED CLINICAL OBSERVATIONS: Yes- Time schedule: dailyBODY WEIGHT: Yes- Time schedule for examinations: weeklyFOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: YesWATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes- Time schedule for examinations: weeklyOPHTHALMOSCOPIC EXAMINATION: Yes- Time schedule for examinations: prior to test and at termination- Dose groups that were examined: all of themHAEMATOLOGY: Yes- Time schedule for collection of blood: at sacrifice- Anaesthetic used for blood collection: not necessary- Animals fasted: Yes- How many animals: all- Parameters examined: hemoglobin concentration, hematocrit, erythrocyte count, reticulocyte count, platelet count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, prothrombin time, activated partial thromboplastin time, total and differential leukocyte counts, erythrocyte morphologyCLINICAL CHEMISTRY: Yes- Time schedule for collection of blood: at sacrifice- Animals fasted: Yes- How many animals: all- Parameters examined: aspartate aminotransferase (serum glutamic oxaloacetic transaminase), alanine aminotransferase (serum glutamic pyruvictransaminase), alkaline phosphatase, blood urea nitrogen, creatinine, fasting glucose, total protein, albumin, globulin (calculated), A/G ratio (calculated), total bilirubin, sodium, potassium, chloride, calcium, inorganic phosphorus, gamma glutamyl transpeptidaseURINALYSIS: Yes- Time schedule for collection of urine: at sacrifice- Metabolism cages used for collection of urine: No- Animals fasted: Yes- Parameters examined: gross appearance, specific gravity, pH, protein, glucose, ketones, bilirubin, occult blood, 16-hour volume, microscopic analysisNEUROBEHAVIOURAL EXAMINATION: No
- Sacrifice and pathology:
- GROSS PATHOLOGY: Yes, complete gross postmortem examinations were performed on all animals: external surface and all orifices; the external surfaces of the brain and spinal cord; the organs and tissues of the cranial, thoracic, abdominal, and pelvic cavities and neck; and the remainder of the carcass.Organs weighed: adrenals, brain, heart, kidneys, liver, ovaries, spleen, testes with epididymides, thyroid/parathyroids, urinary bladderTissues preserved: adrenal glands, aorta (thoracic), bone marrow (sternum), bone (sternum), brain (medulla/pons, cerebrum and cerebellum), epididymides, esophagus, eyes (with optic nerve), femur, heart, kidneys, lacrimal gland, large intestine (cecum, colon, and rectum), liver (at least 2 lobes), lungs (with mainstem bronchi), lymph node (mesenteric), lymph node (mediastinal), mammary gland, muscle (biceps femoris), nerve (sciatic), ovaries, pancreas, pituitary gland, prostate, salivary gland (mandibulbar), seminal vesicles, skin, small intestine (duodenum, jejunum and ileum), spinal cord (thoracic), spleen, stomach, testes, thymus, thyroid gland (with parathyroids), trachea, urinary bladder, uterus (body/horns) with cervix, gross lesionsHISTOPATHOLOGY: Yes, the following tissues were examined for all animals of the low and high dose group. Target organs identified in the high dose animals were also examined in the remaining animals.Tissues examined: adrenal glands, aorta (thoracic), bone marrow (sternum), bone (sternum), brain (medulla/pons, cerebrum and cerebellum), epididymides, esophagus, heart, kidneys, lacrimal gland, large intestine (cecum, colon, and rectum), liver (at least 2 lobes), lungs (with mainstem bronchi), lymph node (mesenteric), lymph node (mediastinal), nerve (sciatic), ovaries, pancreas, pituitary gland, prostate, salivary gland (mandibulbar), small intestine (duodenum, jejunum and ileum), spinal cord (thoracic), spleen, stomach, testes, thymus, thyroid gland (with parathyroids), trachea, urinary bladder, uterus (body/horns) with cervix, gross lesions
- Statistics:
- A standard one way ANOVA using the F distribution to assess significance and a Bartlett's test was performed to determine if groups had equal variance. If the variances were unequal, the Kruskal-Wallis test was used, and if differences were indicated a summed rank test (Dunn) was used to determine which treatments differed from control. If the variances were equal, and significant differences among the means were indicated, Dunnett's test was used to determine which means were significantly different from the control. If mean terminal organ weights had unequal variances, the ratios for these organs were analyzed using the Kruskal-Wallis test. A statistical test for trend in the dose levels was also performed. In the parametric case (i.e., equal variance) standard regression techniques with a test for trend and lack of fit were used. In the nonparametric case Jonckheere's test for monotonic trend was used. The test for equal variance (Bartlett's) was conducted at the 1%, two-sided risk level. All other statistical tests were conducted at the 5% and 1%, two-sided risk level. References for these techniques are Snedecor, G.W., and Cochran, W.G., Statistical Methods, 6th edition, Iowa State University Press (1967); Hollander, M. and Wolfe, D.A., Nonparametric Statistical Methods. John Wiley and Sons, New York (1973); Dunnett, C.W., J. Am. Sta. Assn. Val. 50 (1955) and Biometrics. Val. 20 (1964).
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not examined
- Details on results:
- CLINICAL SIGNS AND MORTALITYNo mortality was observed throughout the study period.BODY WEIGHT AND WEIGHT GAINAll animals gained weight throughout the study. However, weights and weight gains for high-dose males were slightly lower than control values and, at study termination, the difference in mean body weights for these two groups was nine percent.FOOD CONSUMPTION AND COMPOUND INTAKEFood consumption values for treated groups were comparable to control values or exhibited normal variability. No consistent differences considered to represent an effect of test material administration were evident.WATER CONSUMPTION AND COMPOUND INTAKEMean weekly water consumption values for high-dose males were statistically significantly higher than mean control values at most intervals from Week 4 throughout study termination (Week 13). Values for high-dose females and for mid- and low-dose animals of both sexes were comparable to control values or exhibited normal variability. No effect of test material was evident in these groups. Mean weekly test substance intake, calculated from water consumption values and based on nominal concentrations are listed in table 1 under "any other information on results incl. tables".OPHTHALMOSCOPIC EXAMINATIONOphthalmoscopic examinations at study termination revealed no ocular abnormalities considered to be related to test material administration.HAEMATOLOGYTerminal values demonstrated no effect of test material administration. Values for control and treated groups were comparable; no statistically significant differences occurred. Differential leukocyte counts were unremarkable.CLINICAL CHEMISTRYAt study termination, values for control and treated groups were considered comparable. No statistically significant differences occurred and no effect of test material administration was evident.URINALYSISUrinary pH values for the high-dose males and females were slightly but statistically significantly lower than values for control animals at study termination. Ranges and mean values are summarized in table 2 under "any other information on results incl. tables".The differences seen for high-dose animals are statistically significant. Other urinalysis values exhibited normal variability. No differences suggestive of an effect of the test material were apparent.ORGAN WEIGHTSThe mean terminal kidney weight for the high-dose males was slightly higher than the control mean even though the mean terminal body weight for this group was slightly lower than the mean control weight. This resulted in a statistically significant elevation, relative to the control value, in the kidney/body weight ratio which is considered suggestive of an effect of test material administration. Similar differences were not evident for females. Other organ weight values for control and treated groups were generally comparable. The only statistically significant difference (elevated liver/brain weight ratio for high-dose females) was slight and no dose-related trend was evident; this was considered unrelated to test material administration.GROSS PATHOLOGY/HISTOPATHOLOGY: NON-NEOPLASTICGross and microscopic postmortem observations were unremarkable. The few abnormalities which were seen occurred sporadically in treated and control animals with comparable incidence and severities and were not considered attributed to the test material.
Effect levels
open allclose all
- Dose descriptor:
- NOEL
- Effect level:
- ca. 406.4 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: No effects were observed in any of the male animals at this dose.
- Dose descriptor:
- NOEL
- Effect level:
- ca. 495.5 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: No effects were observed in any of the female animals at this dose.
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Table 1 Mean test substance intake
| Concentration [% v/v] | Mean test substance intake [mg/kg/d] | |
Males | Females | ||
Group II | 0.096 | 80-190 | 119-188 |
Group III | 0.32 | 274-667 | 395-703 |
Group IV | 1.6 | 1840-3860 | 2300-3492 |
Table 2 Urinary pH values
| Concentration [% v/v] | Urine pH values – Study Termination | |||
Males | Females | ||||
Meana | Range | Meana | Range | ||
Group I | 0 | 8.6 | 8.0-≥9.0 | 8.6 | 8.0-≥9.0 |
Group II | 0.096 | 8.7 | 8.0-≥9.0 | 8.6 | 8.0-≥9.0 |
Group III | 0.32 | 8.4 | 8.0-≥9.0 | 8.5 | 8.0-≥9.0 |
Group IV | 1.6 | 7.8** | 6.5-8.5 | 7.7** | 6.5-8.5 |
aMeans calculated using 9.0 for values≥9.0.
** p≤0.01
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
